{Reference Type}: Journal Article
{Title}: Comparison of quality of life after bladder augmentation in patients previously treated with intradetrusor botulinum toxin A for neurogenic detrusor overactivity.
{Author}: Bakali Issaui Z;Truong XQ;Genon M;Gaillet S;Tournebise H;Zini P;Bernuz B;Thiry Escudier I;Bardot P;Radot C;Muro C;Lenne Aurier K;Bonopera R;De Brier G;Boissier R;Lechevallier E;Karsenty G;Michel F;
{Journal}: Fr J Urol
{Volume}: 34
{Issue}: 10
{Year}: 2024 Jul 24
暂无{DOI}: 10.1016/j.fjurol.2024.102706
{Abstract}: <B>OBJECTIVE: </B>To compare the quality of life (QoL) in the same patients first treated with botulinum toxin A (BTA) injections for neurogenic detrusor overactivity (NDO) and then with bladder augmentation (BA).<BR><B>METHODS: </B>Retrospective study of patients who had BA after BTA treatment between January 2012 and December 2022. Qualiveen Short Form questionnaires and a 7-level Likert/PGI-I scale to answer the question "How would you describe your quality of life after surgery compared to when you felt your best with BTA injections?" were collated and analyzed.<BR><B>RESULTS: </B>Fifty-two BAs for neurogenic bladder (NDO or low compliance) were performed in patients with a median age of 43years [33; 52] previously treated with BTA. After a median follow-up of 33.5 [13.8; 54.3] months, the median Qualiveen-SF global score after BA was significantly higher than that obtained at best BTA efficacy (1.63 [1; 2.63] vs. 2.63 [1.88; 3], P=0.012), as were the scores for the fear, constraints/restrictions and limitations/inconvenience domains. The median PGI-I score was +3 [2; 3] (truly better QoL) and 85.4% of patients reported a QoL after BA superior to the best QoL under BTA.<BR><B>CONCLUSIONS: </B>BA provides a greater range of QoL improvement than BTA injection for patients who have experienced both treatments. Long-lasting effects and absence of need to perform iterative retreatment were the main reasons.<BR><B>METHODS: </B>